Dibar Nutricional's OTC drugs drew FDA CGMP violations and an import alert over missing testing.
What happened
FDA reviewed records Dibar Nutricional submitted in response to an April 22, 2020, request for records under section 704(a)(4) of the FD&C Act for its facility. FDA found significant CGMP violations for finished OTC drug products, including missing identity testing of incoming components, no finished-product release testing, an inadequate stability program, and unqualified equipment. FDA also stated that all drugs and drug products made by the firm were placed on Import Alert 66-40 on November 6, 2020.
What FDA found
The firm did not test each incoming component lot to verify identity; it relied on random supplier sampling and sensory evaluation.
21 CFR 211.84(d)(1)The firm released OTC drugs without full finished-product testing for identity and strength of active ingredients before distribution.
21 CFR 211.165(a)The firm lacked an adequate stability program, including testing in the marketed container-closure system and testing active ingredients and degradation products over shelf life.
21 CFR 211.166(a)The firm lacked installation and operation qualification documents for manufacturing equipment and recent calibration information, including for scales used to weigh active ingredients.
21 CFR 211.63
What FDA wants
Respond in writing within 15 working days with corrective actions and supporting records; if corrective actions cannot be completed, state the reasons and a completion schedule. FDA also strongly recommends engaging a qualified CGMP consultant.
Who should pay attention
- brands that buy OTC drugs from this contract manufacturer
- US importers and distributors of Dibar drug products
- companies relying on supplier certificates of analysis for component identity
This is a summary. Read the original letter on fda.gov.